MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-04-2026
ChromaDex Corporation DPO Ratio 2011-2026 | CDXC
Annual DPO Ratio ChromaDex Corporation
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 76.3 | 90.1 | 111 | 125 | 140 | 144 | 171 | 225 | 127 | 168 | 126 | - | 74.8 | 134 | 40.3 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 225 | 40.3 | 125 |
Quarterly DPO Ratio ChromaDex Corporation
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100 | 102 | 78.4 | - | 73.3 | 80.7 | 95.1 | - | 117 | 109 | 94 | - | 129 | 136 | 137 | - | 141 | 143 | 177 | - | 151 | 139 | 144 | - | 166 | 181 | 184 | - | 232 | 220 | 176 | - | 107 | 161 | 253 | - | 263 | 116 | 111 | - | 79.8 | 72.1 | 36.1 | - | 87.7 | 86.9 | 73.4 | - | 66.8 | 75.3 | 134 | - | 132 | 164 | 108 | - | 151 | 151 | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 263 | 36.1 | 130 |
DPO Ratio of other stocks in the Biotechnology industry
| Issuer | DPO Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Acorda Therapeutics
ACOR
|
277 | - | -24.86 % | $ 820 K |  USA |
 |
Acasti Pharma
ACST
|
4.39 K | - | 4.01 % | $ 150 M |  Canada |
 |
Advaxis
ADXS
|
143 K | - | -9.65 % | $ 45.9 M | USA |
 |
I-Mab
IMAB
|
2.24 K | - | - | $ 866 M |  China |
 |
AgeX Therapeutics
AGE
|
9.04 K | - | -10.17 % | $ 12.2 K | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
78.2 | - | - | $ 40.3 B | USA |
 |
Albireo Pharma
ALBO
|
1.59 K | - | -0.23 % | $ 916 M | USA |
 |
Aptorum Group Limited
APM
|
405 | $ 0.79 | 0.01 % | $ 4.31 M | China |
 |
Midatech Pharma plc
MTP
|
162 | - | -18.52 % | $ 27.3 M |  Britain |
 |
BioCardia
BCDA
|
68.1 K | $ 1.27 | - | $ 26.9 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
115 | - | - | - |  Russia |
 |
Aeterna Zentaris
AEZS
|
34.4 K | - | 5.93 % | $ 314 M | Canada |
 |
Catalyst Biosciences
CBIO
|
7.82 | $ 11.58 | - | $ 1.03 B | USA |
 |
Cerus Corporation
CERS
|
242 | $ 1.8 | 6.51 % | $ 343 M | USA |
 |
Anika Therapeutics
ANIK
|
54.4 | $ 14.36 | - | $ 210 M | USA |
 |
AVEO Pharmaceuticals
AVEO
|
235 | - | - | $ 521 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
2.21 K | - | - | $ 7.46 M |  Israel |
 |
Aytu BioScience
AYTU
|
186 | $ 2.64 | - | $ 16.6 M | USA |
 |
Cardiff Oncology
CRDF
|
406 | $ 1.9 | - | $ 127 M | USA |
 |
CorMedix
CRMD
|
79.3 | $ 6.54 | - | $ 471 K | USA |